Long-term Use of Adalimumab Yields Promising Benefits For Ulcerative Colitis Patients

Long-term Use of Adalimumab Yields Promising Benefits For Ulcerative Colitis Patients
According to a recent study, prolonged treatment with Adalimumab, a TNF inhibiting anti-inflammatory drug, is beneficial for patients with moderately to severely active ulcerative colitis (UC). The study was conducted at the University of California’s Inflammatory Bowel Disease Center in San Diego by William J. Sandborn, M.D. and colleagues, where they evaluated the safety and efficacy of long-term adalimumab

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *